Basit öğe kaydını göster

dc.contributor.authorGultekin, Melis
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorSezen, Duygu
dc.contributor.authorZorlu, Faruk
dc.contributor.authorYildiz, Ferah
dc.contributor.authorYazici, Gozde
dc.contributor.authorHurmuz, Pervin
dc.contributor.authorOzyigit, Gokhan
dc.contributor.authorAkyol, Fadil
dc.contributor.authorGurkaynak, Murat
dc.date.accessioned2019-12-10T11:30:52Z
dc.date.available2019-12-10T11:30:52Z
dc.date.issued2017
dc.identifier.issn1533-0346
dc.identifier.urihttps://doi.org/10.1177/1533034616655952
dc.identifier.urihttp://hdl.handle.net/11655/15820
dc.description.abstractBackground: This study aimed to evaluate the efficacy and safety of hypofractionated stereotactic radiotherapy for reirradiation of recurrent pediatric tumors. Methods and Materials: The study included 23 pediatric patients who were reirradiated using hypofractionated stereotactic radiotherapy in the radiation oncology department between January 2008 and November 2013. In total, 33 tumors were treated-27 (82%) cranial and 6 (18%) extracranial. Hypofractionated stereotactic radiotherapy was administered due to recurrent disease in 31 (94%) tumors and residual disease in 2 (6%) tumors. The median total dose was 25 Gy (range: 15-40 Gy), and the median follow-up was 20 months (range: 2-68 months). Results: The 1-year and 2-year local control rates in the entire study population were 42% and 31%, respectively. The median local control time was 11 months (range: 0-54 months) following hypofractionated stereotactic radiotherapy. The patients with tumor response after hypofractionated stereotactic radiotherapy had significantly longer local control than the patients with post-hypofractionated stereotactic radiotherapy tumor progression (21 vs 3 months, P < .001). Tumor volume <1.58 cm(3) was correlated (not significantly) with better local control (23 vs 7 months, P = .064). Conclusion: Reirradiation of pediatric tumors using hypofractionated stereotactic radiotherapy is a safe and effective therapeutic approach. This treatment modality should be considered as a treatment option in selected pediatric patients.
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.isversionof10.1177/1533034616655952
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOncology
dc.titleReirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalTechnology In Cancer Research & Treatment
dc.contributor.departmentRadyasyon Onkolojisi
dc.identifier.volume16
dc.identifier.issue2
dc.identifier.startpage195
dc.identifier.endpage202
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster